MindImmune Therapeutics has appointed Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development. Dr. Prod’homme will lead cross-disciplinary preclinical strategy for MindImmune’s pipeline, including its monoclonal antibody candidate MITI-101, designed to prevent the recruitment of neuroinflammatory innate immune cells from the periphery into the brain where they cause damage to brain cells underlying disease. His responsibilities include guiding candidate selection and advancing preclinical studies including CMC, drug safety evaluation and translational biomarkers to support clinical development.
“We couldn’t be more pleased that Thomas has joined the MindImmune team at this critical point in our growth,” said Stevin Zorn, Ph.D., co-founder, President and CEO of MindImmune. “Thomas’s deep experience in translational medicine and immunology, and success in spearheading the filing of multiple IND applications and implementing clinical biomarker strategies will certainly add great value to the advancement of our lead program, MITI-101.”
Dr. Prod’homme is a scientific leader with a 15-year history in drug discovery in both the biotech and pharmaceutical industries. He has demonstrated success in building and leading preclinical and translational research infrastructures and regulatory submissions. Importantly, Dr. Prod’homme has spearheaded the successful filing of multiple IND applications and has authored over 20 scientific publications. Prior to MindImmune, Dr. Prod’homme held various positions of growing responsibilities in pharmaceutical and biotechnology companies, including, most recently, Head of Translational Research at Mirai Bio and Myeloid Therapeutics. Dr. Prod’homme received his Doctor of Philosophy (PhD) in Immunology, from the Université René Descartes in Paris and conducted postdoctoral fellowship studies in the Department of Neurology at University of California San Francisco.
Dr. Prod’homme commented, “Joining the MindImmune team is a great opportunity for me to contribute to the company’s growth and to work alongside its founders who share a collective vision to treat Alzheimer’s disease and other disorders related to neuroinflammation. I look forward to bringing my expertise to advancing MITI-101 and starting IND-enabling work this year.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!